However, we did not find ph+ patients had inferior outcomes than ph- patients in CDKN2A/B deletion groups; this is most likely due to the utilization of tyrosine kinase inhibitors (TKIs) in ph+ patients for the entire duration of ALL therapy (22, 23). Here, CDKN2A is linked to acute lymphoblastic leukemia.